Fig. 1

LATS1 and LATS 2 are frequently mutated and downregulated in patients with EC. (A, B) Schematics of LATS1 (A) and LATS2 (B) proteins showing the positions of individual somatic mutations identified in the TCGA EC cohort. (C) Co-occurrence of LATS1 and LATS2 mutations in the TCGA EC cohort. (D) Genetic alteration of LATS1 and LATS2 in the TCGA EC cohort. (E, F) Kaplan–Meier survival curves for patients with LATS1 (E) or LATS2 (F) mutated and wild-type EC from the TCGA cohort. (G) Kaplan–Meier survival curves for patients with LATS1 or LAST2 mutated, LATS1/2 mutated, and LATS1/2 wild-type EC in the TCGA EC cohort. (H, I) Relative mRNA expression of LATS1 (H) or LATS2 (I) in normal endometrial tissues and EC tissues from the TCGA cohort. (J, K) IHC analysis of LATS1 in normal endometrial and EC tissues from our sample cohort (J). Scale bar, 50 μm. Quantitative data for LATS1 protein staining in (K). (L, M) IHC analysis of LATS2 in normal endometrial and EC tissues from our sample cohort (L). Scale bar, 50 μm. Quantitative data for LATS2 protein staining in (M). (N, O) LATS1 (N) or LATS2 (O) protein expression in EC at different FIGO stages from our sample cohort. P values are calculated using the Student’s t-test in (H, I), the Mann-Whitney test in (K, M) and the Kruskal-Wallis test in (N, O). *p < 0.05, **p < 0.01, ***p < 0.001